US Edition
MIT Advances Implantable Hypoglycemia Rescue Device Toward Year-Long Use
MIDDLESEX COUNTY, MASSACHUSETTS, JUL 9 – The MIT-developed implant delivers emergency glucagon automatically or manually to prevent hypoglycemia in Type 1 diabetes, with potential for multi-dose use over months, researchers say.
- MIT engineers have developed a coin-sized implantable reservoir that automatically releases glucagon to treat hypoglycemia in Type 1 diabetes emergencies.
- People with Type 1 diabetes face constant hypoglycemia risk, especially during sleep or in children, prompting MIT to develop an automatic glucagon delivery device.
- Specifically, the coin-sized implant houses a 3D-printed polymer reservoir of stable powdered glucagon sealed by a nickel-titanium alloy curling at 40°C, and its antenna enables wireless triggering by glucose monitors.
- MIT's preclinical tests show the device normalizes blood sugar within 10 minutes and remains effective despite scar tissue formation.
- MIT researchers plan to initiate human clinical trials within three years, aiming to expand applications to emergency epinephrine delivery for heart attacks and allergies.
14 Articles
14 Articles
This tiny implant could save diabetics from silent, deadly crashes
MIT engineers have developed a tiny implantable device that could revolutionize emergency treatment for people with Type 1 diabetes. The device contains a powdered form of glucagon and can be remotely triggered—either manually or automatically by a glucose monitor—to release the hormone when blood sugar drops too low. This offers a potentially life-saving safety net, especially during sleep or for young children.
New implantable device could save diabetes patients from low blood sugar levels—No injections needed!
US researchers have developed a tiny implantable device that automatically releases glucagon to prevent life-threatening low blood sugar in Type 1 diabetics, eliminating the need for emergency injections.
Implantable device could save diabetes patients from dangerously low blood sugar
MIT engineers developed an implantable reservoir that can remain under the skin and be triggered to release glucagon when people with diabetes are in danger of becoming hypoglycemic.
MIT develops implantable device to automatically release emergency glucagon
For people with Type 1 diabetes, developing hypoglycemia, or low blood sugar, is an ever-present threat. When glucose levels become extremely low, it creates a life-threatening situation for which the standard treatment of care is injecting a hormone called glucagon.
Coverage Details
Bias Distribution
- 67% of the sources are Center
To view factuality data please Upgrade to Premium
